ES8601109A1 - Procedimiento para preparar suspensiones de cristales de uno o mas derivados de insulina - Google Patents

Procedimiento para preparar suspensiones de cristales de uno o mas derivados de insulina

Info

Publication number
ES8601109A1
ES8601109A1 ES534684A ES534684A ES8601109A1 ES 8601109 A1 ES8601109 A1 ES 8601109A1 ES 534684 A ES534684 A ES 534684A ES 534684 A ES534684 A ES 534684A ES 8601109 A1 ES8601109 A1 ES 8601109A1
Authority
ES
Spain
Prior art keywords
procedure
insulin derivatives
preparing glass
amino acid
glass suspensions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES534684A
Other languages
English (en)
Spanish (es)
Other versions
ES534684A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of ES534684A0 publication Critical patent/ES534684A0/es
Publication of ES8601109A1 publication Critical patent/ES8601109A1/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C07K14/622—Insulins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ES534684A 1983-07-29 1984-07-27 Procedimiento para preparar suspensiones de cristales de uno o mas derivados de insulina Expired ES8601109A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19833327709 DE3327709A1 (de) 1983-07-29 1983-07-29 Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung

Publications (2)

Publication Number Publication Date
ES534684A0 ES534684A0 (es) 1985-10-16
ES8601109A1 true ES8601109A1 (es) 1985-10-16

Family

ID=6205461

Family Applications (1)

Application Number Title Priority Date Filing Date
ES534684A Expired ES8601109A1 (es) 1983-07-29 1984-07-27 Procedimiento para preparar suspensiones de cristales de uno o mas derivados de insulina

Country Status (20)

Country Link
US (1) US4959351A (enExample)
EP (1) EP0133285B1 (enExample)
JP (1) JPH0764876B2 (enExample)
KR (1) KR910009344B1 (enExample)
AT (1) ATE32729T1 (enExample)
AU (1) AU567360B2 (enExample)
CA (1) CA1246549A (enExample)
DE (2) DE3327709A1 (enExample)
DK (1) DK172241B1 (enExample)
ES (1) ES8601109A1 (enExample)
FI (1) FI80277C (enExample)
GR (1) GR82438B (enExample)
HU (1) HU201096B (enExample)
IE (1) IE57711B1 (enExample)
IL (1) IL72512A (enExample)
NO (1) NO167207C (enExample)
NZ (1) NZ209041A (enExample)
PH (1) PH22649A (enExample)
PT (1) PT78980A (enExample)
ZA (1) ZA845819B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946828A (en) * 1985-03-12 1990-08-07 Novo Nordisk A/S Novel insulin peptides
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides
DK119785D0 (da) * 1985-03-15 1985-03-15 Nordisk Gentofte Insulinpraeparat
DE3604868A1 (de) * 1986-02-15 1987-08-20 Behringwerke Ag Insulinderivate, verfahren zu ihrer herstellung und ihre verwendung
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DE3844211A1 (de) * 1988-12-29 1990-07-05 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DK134189D0 (da) * 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
WO1992010284A2 (en) 1990-12-07 1992-06-25 Cnc Development, Inc. Catalytic chemical reactor
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
JP2837956B2 (ja) 1993-06-21 1998-12-16 ノボ ノルディスク アクティーゼルスカブ Ａｓｐ▲上Ｂ２８▼インスリン結晶
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
WO1997005166A1 (en) 1995-07-25 1997-02-13 Novartis Ag Transforming growth factor beta crystals
PT821006E (pt) * 1996-07-26 2004-09-30 Aventis Pharma Gmbh Derivados de insulina com ligacao a zinco aumentada
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
ATE294189T1 (de) * 1997-02-07 2005-05-15 Novo Nordisk As Kristallisation von proteinen
JP2001521006A (ja) 1997-10-24 2001-11-06 イーライ・リリー・アンド・カンパニー 不溶性インシュリン組成物
US6531448B1 (en) 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
DE19825447A1 (de) * 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
KR20030074693A (ko) 2000-12-28 2003-09-19 알투스 바이올로직스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
CN100439397C (zh) * 2001-02-09 2008-12-03 基因技术股份有限公司 Igf-1的结晶
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
NZ530700A (en) * 2001-06-21 2009-02-28 Altus Pharmaceuticals Inc Spherical protein particles and methods of making and using them
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
PL373543A1 (pl) * 2005-03-10 2006-09-18 Instytut Biotechnologii i Antybiotyków Kompozycja farmaceutyczna zawierająca biosyntetyczny analog insuliny ludzkiej, oraz jej zastosowanie w terapii cukrzycy
WO2008065138A1 (en) * 2006-11-29 2008-06-05 Novo Nordisk A/S Novel insulin crystal and method for preparing the crystal
PL219335B1 (pl) * 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
CN102596175A (zh) 2009-07-06 2012-07-18 赛诺菲-安万特德国有限公司 含有甲硫氨酸的水性胰岛素制备物
MY180661A (en) 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
PL2611458T3 (pl) 2010-08-30 2017-02-28 Sanofi-Aventis Deutschland Gmbh Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
CN102219851B (zh) * 2011-05-09 2012-05-30 甘李药业有限公司 甘精胰岛素结晶的制备方法
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2014161835A1 (en) * 2013-04-03 2014-10-09 Sanofi Modified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof
US9822158B2 (en) * 2013-12-04 2017-11-21 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB729670A (en) * 1951-11-15 1955-05-11 Novo Terapeutisk Labor As Improved process for the production of insulin in crystalline form and crystalline insulin produced thereby
DK78069C (da) * 1952-06-23 1954-09-06 Novo Terapeutisk Labor As Fremgangsmåde til fremstilling af krystallinsk insulin.
US3719655A (en) * 1969-12-05 1973-03-06 Lilly Co Eli Process for the crystallization of the ammonium and alkali metal salts in insulin
DE2459515C3 (de) * 1974-12-17 1982-02-11 Hoechst Ag, 6000 Frankfurt Arzneimittelzubereitungen mit antidiabetischer Wirkung
DK319780A (da) * 1980-07-24 1982-01-25 Forenede Bryggerier As Fremgangsmaade til enzymatisk udskiftning af b-30 aminosyren i insuliner
NL8201650A (nl) * 1982-04-21 1983-11-16 Akzo Nv Semisynthetische bereiding van humane insuline.
DE3327928A1 (de) * 1983-08-03 1985-02-21 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von insulin-derivaten

Also Published As

Publication number Publication date
US4959351A (en) 1990-09-25
FI842981A0 (fi) 1984-07-26
NO843048L (no) 1985-01-30
CA1246549A (en) 1988-12-13
PH22649A (en) 1988-10-28
AU3127284A (en) 1985-01-31
JPH0764876B2 (ja) 1995-07-12
PT78980A (de) 1984-08-01
IL72512A (en) 1989-08-15
DE3327709A1 (de) 1985-02-07
ZA845819B (en) 1985-03-27
NZ209041A (en) 1989-02-24
ES534684A0 (es) 1985-10-16
AU567360B2 (en) 1987-11-19
DK172241B1 (da) 1998-02-02
HUT35001A (en) 1985-05-28
EP0133285A1 (de) 1985-02-20
IL72512A0 (en) 1984-11-30
FI842981A7 (fi) 1985-01-30
DK368884D0 (da) 1984-07-27
HU201096B (en) 1990-09-28
DK368884A (da) 1985-01-30
IE57711B1 (en) 1993-03-10
KR910009344B1 (ko) 1991-11-12
NO167207B (no) 1991-07-08
ATE32729T1 (de) 1988-03-15
FI80277B (fi) 1990-01-31
JPS6051118A (ja) 1985-03-22
NO167207C (no) 1991-10-16
GR82438B (enExample) 1984-12-13
EP0133285B1 (de) 1988-03-02
IE841947L (en) 1985-01-29
KR850000981A (ko) 1985-03-14
FI80277C (fi) 1990-05-10
DE3469535D1 (en) 1988-04-07

Similar Documents

Publication Publication Date Title
ES8601109A1 (es) Procedimiento para preparar suspensiones de cristales de uno o mas derivados de insulina
ES534488A0 (es) Procedimiento para preparar una suspension de un derivado de insulina
ES8504678A1 (es) Procedimiento para la preparacion de un derivado de insulina
DK669889D0 (da) Insulinderivater, deres fremstilling og anvendelse
IL76107A (en) Method of removing n-terminal amino acid residues from eucaryotic polypeptide analogs and polypeptides produced thereby
ES2093717T3 (es) Mutante de hirudina, su produccion, anticoagulante, vector secretor, microorganismo transformado por el indicado vector y produccion de un producto a partir de dicho microorganismo.
HUT55804A (en) Process for producing new insulin derivatives and pharmaceutical compositions containing them as active components
ATE176243T1 (de) Pacap-derivate mit c-amp-produzierenden eigenschaften
ES2196088T3 (es) Analogos del factor de crecimiento de los queratinocitos.
KR850001775A (ko) 인슐린 유도체의 제조방법
KR870004139A (ko) 인체 λ-인터페론의 생물학적 활성 유도체를 제조하는 방법
DE2963675D1 (en) A process for inverting the configuration in optically active compounds and optically active intermediate compounds and their salts required therefor
ATE15654T1 (de) Ester von 2,2-dimethyl-3-formyl-1cyclopropancarbons|ure.
GB1530921A (en) Desacylpepsidine and the preparation thereof
NZ215994A (en) Culturing e.coli to produce interferon alpha and gamma and interleukin-2
ATE186570T1 (de) Wachstumshormon-releasingfaktor-analoge
ES8200142A1 (es) Un procedimiento para la produccion de analogos de cefalosporina.
ATE142270T1 (de) Acetylierte heterologe polypeptide
KR890009783A (ko) 니오브산리튬 단결정의 제조방법
JPS643160A (en) (2-cyano-2-oxyiminoacetyl)-amino acid derivative
GB445455A (en) Improvements in or relating to electro-therapeutic bath apparatus